Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 570

1.

Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma.

Ho AS, Ochoa A, Jayakumaran G, Zehir A, Valero Mayor C, Tepe J, Makarov V, Dalin MG, He J, Bailey M, Montesion M, Ross JS, Miller VA, Chan L, Ganly I, Dogan S, Katabi N, Tsipouras P, Ha P, Agrawal N, Solit DB, Futreal PA, El Naggar AK, Reis-Filho JS, Weigelt B, Ho AL, Schultz N, Chan TA, Morris LG.

J Clin Invest. 2019 Oct 1;129(10):4276-4289. doi: 10.1172/JCI128227.

2.

Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland.

Bell D, Ferrarotto R, Liang L, Goepfert RP, Li J, Ning J, Broaddus R, Weber RS, El-Naggar AK.

Virchows Arch. 2019 Aug 19. doi: 10.1007/s00428-019-02640-7. [Epub ahead of print]

PMID:
31423558
3.

Editor's Note: Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer.

Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN, Holsinger FC, Sherman SI, Yeung SC, El-Naggar AK, Myers JN.

Clin Cancer Res. 2019 Aug 1;25(15):4862. doi: 10.1158/1078-0432.CCR-19-2052. No abstract available.

PMID:
31371312
4.

Editor's Note: Identification of Insulin-Like Growth Factor Binding Protein-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma.

Oh SH, Kim WY, Kim JH, Younes MN, El-Naggar AK, Myers JN, Kies M, Cohen P, Khuri F, Hong WK, Lee HY.

Clin Cancer Res. 2019 Aug 1;25(15):4861. doi: 10.1158/1078-0432.CCR-19-2054. No abstract available.

PMID:
31371311
5.

Ectopic ACTH Production and Cushing's Syndrome in a Patient with Parotid Acinic Cell Carcinoma with High-Grade Transformation: Tumor Context and Clinical Implications.

Saluja K, Ravishankar S, Ferrarotto R, Zhu H, Pytynia KB, El-Naggar AK.

Head Neck Pathol. 2019 Jul 30. doi: 10.1007/s12105-019-01054-w. [Epub ahead of print]

PMID:
31363907
6.

Dicer1 Phosphomimetic Promotes Tumor Progression and Dissemination.

Aryal NK, Pant V, Wasylishen AR, Rimel BJ, Baseler L, El-Naggar AK, Mutch DG, Goodfellow PJ, Arur S, Lozano G.

Cancer Res. 2019 May 15;79(10):2662-2668. doi: 10.1158/0008-5472.CAN-18-2460. Epub 2019 Mar 26.

PMID:
30914430
7.

GLIS Rearrangement is a Genomic Hallmark of Hyalinizing Trabecular Tumor of the Thyroid Gland.

Nikiforova MN, Nikitski AV, Panebianco F, Kaya C, Yip L, Williams M, Chiosea SI, Seethala RR, Roy S, Condello V, Santana-Santos L, Wald AI, Carty SE, Ferris RL, El-Naggar AK, Nikiforov YE.

Thyroid. 2019 Feb;29(2):161-173. doi: 10.1089/thy.2018.0791.

PMID:
30648929
8.

Constitutive Dicer1 phosphorylation accelerates metabolism and aging in vivo.

Aryal NK, Pant V, Wasylishen AR, Parker-Thornburg J, Baseler L, El-Naggar AK, Liu B, Kalia A, Lozano G, Arur S.

Proc Natl Acad Sci U S A. 2019 Jan 15;116(3):960-969. doi: 10.1073/pnas.1814377116. Epub 2018 Dec 28.

9.

PI3-kinase pathway biomarkers in oral cancer and tumor immune cells.

Ibrahim MY, Nunez MI, Harun N, Lee JJ, El-Naggar AK, Ferrarotto R, Wistuba I, Myers J, Glisson BS, William WN Jr.

Head Neck. 2019 Mar;41(3):615-622. doi: 10.1002/hed.25350. Epub 2018 Dec 16.

PMID:
30556200
10.

Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.

Saintigny P, Mitani Y, Pytynia KB, Ferrarotto R, Roberts DB, Weber RS, Kies MS, Maity SN, Lin SH, El-Naggar AK.

Cancer. 2018 Sep 15;124(18):3693-3705. doi: 10.1002/cncr.31600. Epub 2018 Oct 5.

11.

Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases.

Zhang Y, Xiong S, Liu B, Pant V, Celii F, Chau G, Elizondo-Fraire AC, Yang P, You MJ, El-Naggar AK, Navin NE, Lozano G.

Nat Commun. 2018 Sep 27;9(1):3953. doi: 10.1038/s41467-018-06146-9.

12.

A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, Busam KJ, de Krijger RR, Dietel M, El-Naggar AK, Fernandez-Cuesta L, Klöppel G, McCluggage WG, Moch H, Ohgaki H, Rakha EA, Reed NS, Rous BA, Sasano H, Scarpa A, Scoazec JY, Travis WD, Tallini G, Trouillas J, van Krieken JH, Cree IA.

Mod Pathol. 2018 Dec;31(12):1770-1786. doi: 10.1038/s41379-018-0110-y. Epub 2018 Aug 23.

13.

Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy.

Ileana Dumbrava E, Smith V, Alfattal R, El-Naggar AK, Penas-Prado M, Tsimberidou AM.

J Immunother. 2018 Sep;41(7):336-339. doi: 10.1097/CJI.0000000000000224.

14.

Incompletely treated malignancies of the major salivary gland: Toward evidence-based care.

Tam S, Sandulache VC, Metwalli KA, Rock CD, Eraj SA, Sheu T, El-Naggar AK, Fuller CD, Weber RS, Lai SY.

Head Neck. 2018 Aug;40(8):1630-1638. doi: 10.1002/hed.25156. Epub 2018 May 7.

PMID:
29734482
15.

Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) in thyroid tumor classification.

Kakudo K, El-Naggar AK, Hodak SP, Khanafshar E, Nikiforov YE, Nosé V, Thompson LDR.

Pathol Int. 2018 Jun;68(6):327-333. doi: 10.1111/pin.12673. Epub 2018 Apr 19. No abstract available.

PMID:
29675873
16.

Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer.

Saintigny P, William WN Jr, Foy JP, Papadimitrakopoulou V, Lang W, Zhang L, Fan YH, Feng L, Kim ES, El-Naggar AK, Lee JJ, Mao L, Hong WK, Lingen MW, Lippman SM.

J Natl Cancer Inst. 2018 Mar 1;110(3). doi: 10.1093/jnci/djx186.

17.

Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer.

Kamal M, Ng SP, Eraj SA, Rock CD, Pham B, Messer JA, Garden AS, Morrison WH, Phan J, Frank SJ, El-Naggar AK, Johnson JM, Ginsberg LE, Ferrarotto R, Lewin JS, Hutcheson KA, Cardenas CE, Zafereo ME, Lai SY, Hessel AC, Weber RS, Gunn GB, Fuller CD, Mohamed ASR, Rosenthal DI.

Oral Oncol. 2018 Apr;79:1-8. doi: 10.1016/j.oraloncology.2018.01.025. Epub 2018 Feb 10.

18.

Transcriptomes define distinct subgroups of salivary gland adenoid cystic carcinoma with different driver mutations and outcomes.

Frerich CA, Brayer KJ, Painter BM, Kang H, Mitani Y, El-Naggar AK, Ness SA.

Oncotarget. 2017 Dec 23;9(7):7341-7358. doi: 10.18632/oncotarget.23641. eCollection 2018 Jan 26.

19.

Frequent and differential mutations of the CYLD gene in basal cell salivary neoplasms: linkage to tumor development and progression.

Rito M, Mitani Y, Bell D, Mariano FV, Almalki ST, Pytynia KB, Fonseca I, El-Naggar AK.

Mod Pathol. 2018 Jul;31(7):1064-1072. doi: 10.1038/s41379-018-0018-6. Epub 2018 Feb 20.

20.

World Health Organization 4th edition of head and neck tumor classification: insight into the consequential modifications.

Slootweg PJ, El-Naggar AK.

Virchows Arch. 2018 Mar;472(3):311-313. doi: 10.1007/s00428-018-2320-6. Epub 2018 Feb 15. No abstract available.

PMID:
29450648
21.

Synergistic and additive effect of retinoic acid in circumventing resistance to p53 restoration.

Larsson CA, Moyer SM, Liu B, Michel KA, Pant V, Yang P, Wong J, El-Naggar AK, Krahe R, Lozano G.

Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):2198-2203. doi: 10.1073/pnas.1719001115. Epub 2018 Feb 13.

22.

Malignant perivascular epithelioid cell tumor of the oropharynx with strong TFE3 expression mimicking alveolar soft part sarcoma: a case report and review of the literature.

Saluja K, Thomas J, Zhang S, Sturgis EM, Jain KS, Prieto VG, El-Naggar AK, Bell D.

Hum Pathol. 2018 Jun;76:149-155. doi: 10.1016/j.humpath.2017.11.016. Epub 2017 Dec 5. Review.

PMID:
29208563
23.

Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma.

Liu B, Mitani Y, Rao X, Zafereo M, Zhang J, Zhang J, Futreal PA, Lozano G, El-Naggar AK.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx033.

24.

PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.

Wang J, Xie T, Wang B, William WN Jr, Heymach JV, El-Naggar AK, Myers JN, Caulin C.

Cancer Prev Res (Phila). 2017 Dec;10(12):684-693. doi: 10.1158/1940-6207.CAPR-17-0108. Epub 2017 Oct 10.

25.

Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma.

Zhang H, Kim S, Chen Z, Nannapaneni S, Chen AY, Moore CE, Sica G, Mosunjac M, Nguyen MLT, D'Souza G, Carey TE, Peterson LA, McHugh JB, Graham M, Komarck CM, Wolf GT, Walline HM, Bellile E, Riddell J 4th, Pai SI, Sidransky D, Westra WH, William WN Jr, Lee JJ, El-Naggar AK, Ferris RL, Seethala R, Grandis JR, Chen ZG, Saba NF, Shin DM; Head and Neck Cancer SPORE HIV supplement consortium.

Head Neck. 2017 Dec;39(12):2433-2443. doi: 10.1002/hed.24911. Epub 2017 Sep 25.

26.

Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes.

Ortiz GJ, Li Y, Post SM, Pant V, Xiong S, Larsson CA, El-Naggar AK, Johnson DG, Lozano G.

Oncogene. 2018 Jan 18;37(3):332-340. doi: 10.1038/onc.2017.344. Epub 2017 Sep 18.

27.

Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck Cancer.

Rosenthal DI, Mohamed ASR, Garden AS, Morrison WH, El-Naggar AK, Kamal M, Weber RS, Fuller CD, Peters LJ.

Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1002-1011. doi: 10.1016/j.ijrobp.2017.02.218. Epub 2017 Jul 10.

28.

What Is New in the World Health Organization 2017 Histopathology Classification?

El-Naggar AK.

Curr Treat Options Oncol. 2017 Jul;18(7):43. doi: 10.1007/s11864-017-0469-x. No abstract available.

PMID:
28639231
29.

The fourth edition of the head and neck World Health Organization blue book: editors' perspectives.

El-Naggar AK, Chan JKC, Takata T, Grandis JR, Slootweg PJ.

Hum Pathol. 2017 Aug;66:10-12. doi: 10.1016/j.humpath.2017.05.014. Epub 2017 Jun 2. No abstract available.

PMID:
28583885
30.

Establishment and genomic characterization of primary salivary duct carcinoma cell line.

Li J, Mitani Y, Rao PH, Perlaky L, Liu B, Weber RS, El-Naggar AK.

Oral Oncol. 2017 Jun;69:108-114. doi: 10.1016/j.oraloncology.2017.04.007. Epub 2017 May 2.

31.

Middle ear adenomatous neuroendocrine tumors: a 25-year experience at MD Anderson Cancer Center.

Bell D, El-Naggar AK, Gidley PW.

Virchows Arch. 2017 Nov;471(5):667-672. doi: 10.1007/s00428-017-2155-6. Epub 2017 May 26.

PMID:
28547535
32.

Mucoepidermoid carcinoma post-radioactive iodine treatment of papillary thyroid carcinoma: unique presentation and putative etiologic association.

Saluja K, Butler RT, Pytynia KB, Zhao B, Karni RJ, Weber RS, El-Naggar AK.

Hum Pathol. 2017 Oct;68:189-192. doi: 10.1016/j.humpath.2017.04.019. Epub 2017 May 10.

PMID:
28499545
33.

Editor's perspective on the 4th edition of the WHO head and neck tumor classification.

El-Naggar AK.

J Egypt Natl Canc Inst. 2017 Jun;29(2):65-66. doi: 10.1016/j.jnci.2017.03.003. Epub 2017 Apr 25. No abstract available.

34.

Chromosomal abnormalities and molecular landscape of metastasizing mucinous salivary adenocarcinoma.

Panaccione A, Zhang Y, Mi Y, Mitani Y, Yan G, Prasad ML, McDonald WH, El-Naggar AK, Yarbrough WG, Ivanov SV.

Oral Oncol. 2017 Mar;66:38-45. doi: 10.1016/j.oraloncology.2016.12.011. Epub 2017 Jan 9.

35.

Intrapartum fetal head circumference and estimated fetal weight as predictors of operative delivery.

Rabei NH, El-Helaly AM, Farag AH, El-Naggar AK, Etman MK, El-Moteily MM.

Int J Gynaecol Obstet. 2017 Apr;137(1):34-39. doi: 10.1002/ijgo.12098. Epub 2017 Feb 2.

PMID:
28099750
36.

The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen-Tan PF, Trotti A, Skinner H, Zhang Q, Ferris RL, Sidransky D, Chung CH.

JAMA Oncol. 2017 Apr 1;3(4):483-491. doi: 10.1001/jamaoncol.2016.5478.

37.

Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.

Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN Jr, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV.

J Clin Oncol. 2017 Jan 20;35(3):352-360. doi: 10.1200/JCO.2016.67.5264. Epub 2016 Nov 21.

38.

Long-term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches.

Fuller CD, Mohamed AS, Garden AS, Gunn GB, Mulcahy CF, Zafereo M, Phan J, Lai SY, Lewin JS, Hutcheson KA, Frank SJ, Beadle BM, Morrison WH, El-Naggar AK, Kocak-Uzel E, Ginsberg LE, Kies MS, Weber RS, Rosenthal DI.

Head Neck. 2016 Dec;38(12):1739-1751. doi: 10.1002/hed.24532. Epub 2016 Jul 28. Erratum in: Head Neck. 2017 Jul;39(7):1484-1496.

39.

Cdkn2a suppresses metastasis in squamous cell carcinomas induced by the gain-of-function mutant p53(R172H).

Li Z, Gonzalez CL, Wang B, Zhang Y, Mejia O, Katsonis P, Lichtarge O, Myers JN, El-Naggar AK, Caulin C.

J Pathol. 2016 Oct;240(2):224-34. doi: 10.1002/path.4770.

PMID:
27447534
40.

Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses.

Takiar V, Garden AS, Ma D, Morrison WH, Edson M, Zafereo ME, Gunn GB, Fuller CD, Beadle B, Frank SJ, William WN Jr, Kies M, El-Naggar AK, Weber R, Rosenthal DI, Phan J.

Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1117-31. doi: 10.1016/j.ijrobp.2016.03.015. Epub 2016 Mar 19.

PMID:
27354127
41.

HPV and oropharyngeal cancer mystery: a glimmer of hope!

El-Naggar AK.

Oral Dis. 2016 Nov;22(8):715. doi: 10.1111/odi.12494. Epub 2016 Aug 22. No abstract available.

PMID:
27095118
42.

Squamous cell carcinoma of the oral cavity often overexpresses p16 but is rarely driven by human papillomavirus.

Zafereo ME, Xu L, Dahlstrom KR, Viamonte CA, El-Naggar AK, Wei Q, Li G, Sturgis EM.

Oral Oncol. 2016 May;56:47-53. doi: 10.1016/j.oraloncology.2016.03.003. Epub 2016 Mar 21.

43.

Novel t(1;3)(q21,p21) translocation in a basal cell adenocarcinoma of the parotid gland: potential association with tumorigenesis.

Saluja K, Rao PH, Myers JN, El-Naggar AK.

Hum Pathol. 2016 Aug;54:189-92. doi: 10.1016/j.humpath.2016.03.019. Epub 2016 Apr 13.

PMID:
27085552
44.

Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors.

Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, El-Naggar AK, Gooding WE, Hodak SP, Lloyd RV, Maytal G, Mete O, Nikiforova MN, Nosé V, Papotti M, Poller DN, Sadow PM, Tischler AS, Tuttle RM, Wall KB, LiVolsi VA, Randolph GW, Ghossein RA.

JAMA Oncol. 2016 Aug 1;2(8):1023-9. doi: 10.1001/jamaoncol.2016.0386.

45.

The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck.

Jiang W, Mohamed AS, Fuller CD, Kim BY, Tang C, Gunn GB, Hanna EY, Frank SJ, Su SY, Diaz E, Kupferman ME, Beadle BM, Morrison WH, Skinner H, Lai SY, El-Naggar AK, DeMonte F, Rosenthal DI, Garden AS, Phan J.

Pract Radiat Oncol. 2016 Jul-Aug;6(4):241-7. doi: 10.1016/j.prro.2015.10.023. Epub 2015 Nov 10.

46.

An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma.

Drier Y, Cotton MJ, Williamson KE, Gillespie SM, Ryan RJ, Kluk MJ, Carey CD, Rodig SJ, Sholl LM, Afrogheh AH, Faquin WC, Queimado L, Qi J, Wick MJ, El-Naggar AK, Bradner JE, Moskaluk CA, Aster JC, Knoechel B, Bernstein BE.

Nat Genet. 2016 Mar;48(3):265-72. doi: 10.1038/ng.3502. Epub 2016 Feb 1.

47.

Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations.

Mitani Y, Liu B, Rao PH, Borra VJ, Zafereo M, Weber RS, Kies M, Lozano G, Futreal PA, Caulin C, El-Naggar AK.

Clin Cancer Res. 2016 Feb 1;22(3):725-33. doi: 10.1158/1078-0432.CCR-15-2867-T. Epub 2015 Dec 2.

48.

Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer.

Nien HH, Sturgis EM, Kies MS, El-Naggar AK, Morrison WH, Beadle BM, Johnson FM, Gunn GB, Fuller CD, Phan J, Gold KA, Frank SJ, Skinner H, Rosenthal DI, Garden AS.

Head Neck. 2016 Apr;38 Suppl 1:E1554-61. doi: 10.1002/hed.24278. Epub 2015 Nov 23.

PMID:
26595157
49.

Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas.

Jiang W, Chamberlain PD, Garden AS, Kim BY, Ma D, Lo EJ, Bell D, Gunn GB, Fuller CD, Rosenthal DI, Beadle BM, Frank SJ, Morrison WH, El-Naggar AK, Glisson BS, Sturgis EM, Phan J.

Head Neck. 2016 Apr;38 Suppl 1:E1459-66. doi: 10.1002/hed.24258. Epub 2015 Nov 11.

50.

Editorial: How clinically significant is minimal extrathyroidal extension in papillary thyroid cancer?

Perrier ND, El-Naggar AK.

Surgery. 2016 Jan;159(1):22. doi: 10.1016/j.surg.2015.07.048. Epub 2015 Oct 27. No abstract available.

PMID:
26518390

Supplemental Content

Loading ...
Support Center